Bio Innovation is
Our Mission
We are a pharmaceutical biotechnology company focusing on antibody and bacteriophage therapies to address unmet medical needs.
Our cutting-edge research aims to develop novel treatments for resistant infections and complex diseases, providing new hope for patients.
Diabetic
Retinophaty
Ocular Surface Infection
Diabetic Foot
Infection
Atopic
Dermatitis
Respiratory
Infection
Our Technology
Our advanced technology platform is driving innovation in antibody and bacteriophage therapies to meet critical unmet medical needs. By leveraging the precision of engineered antibodies and the unique capabilities of bacteriophages, we are developing targeted treatments to resistant infections and complex diseases.
Our technologies enable us to design highly specific, effective, and safe therapeutic solutions, pushing the boundaries of modern medicine and transforming patient care.
Welcome to Lxbio, where the future of biopharmaceuticals is being redefined. As a newly established pharmaceutical company, we present a compelling opportunity for investors seeking to be at the forefront of groundbreaking innovation in the global biopharmaceutical market.
Invest with us
News
Lxbio has inaugurated the Iberian Peninsula’s first laboratory dedicated to CAR-T cells and monoclonal antibodies, with an initial €4 million investment set to reach €20 million.
Operating as a CRO at the University of Lisbon, the facility supports advanced therapy development and has already secured its first international contract, positioning Lisbon as a growing biotechnology hub.
We are very pleased to announce the entry of a new investor into Lxbio Pharmaceuticals S.A., reinforcing the company’s momentum as it moves into its next phase of growth.
LxBio is officially a member of PhageEU, a Brussels-based coalition that aims to raise the potential of phages in Europe, representing this innovative solution in industry, the scientific community and civil society.
The main mission of this team, which LxBio proudly joins as a Portuguese company, is to democratize access to phage technology in the European Union, strengthening the community who works in both industry and academia on phage services and products.
